Publications

1. Ibrutinib (Imbruvica®) for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)

   The National Health Care Institute has completed its assessment whether ibrutinib (Imbruvica®) for the treatment of adult ...

   Report | 03-07-2020

2. GVS assessment of Trifarotene (50 microgram/gram cream) (Aklief®) for the cutaneous treatment of acne vulgaris on the face and torso in patients aged 12 years and over

   The National Health Care Institute has completed its assessment whether trifarotene (50 microgram/gram cream) (Aklief®) for the ...

   Report | 11-06-2020

3. Package advice dabrafenib/trametinib (Tafinlar®/Mekinist®)

   Zorginstituut Nederland has completed its reassessment of the pharmaco-economic analysis of dabrafenib in combination with ...

   Report | 02-06-2020

4. International strategic agenda 2020 National Health Care Institute

   The international strategic agenda 2020 describes the international activities of the National Health Care Institute ...

   Publication | 31-05-2020

5. Oral semaglutide (Rybelsus®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus

   The National Health Care Institute has completed its assessment whether oral semaglutide (Rybelsus®) is interchangeable with a ...

   Report | 29-05-2020

6. Specialist medicinal products assessment procedure

   Zorginstituut Nederland only assesses specialist medicinal products that pose a risk to the accessibility, affordability or ...

   Report | 11-05-2020

7. Pentosan polysulfate sodium (Elmiron®) for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions

   The National Health Care Institute has completed its assessment whether pentosan polysulfate sodium (Elmiron®) is interchangeable ...

   Report | 28-04-2020

8. 12 SQ-HDM SLIT (Itulazax®) for the treatment of allergic rhinitis or conjunctivitis induced by pollen from the birch homologous group

   The National Health Care Institute has completed its assessment whether 12 SQ-HDM SLIT (Itulazax®) is interchangeable with a ...

   Report | 28-04-2020

9. Asfotase alfa (Strensiq ®) for the treatment of hypophosphatasia (HPP)

   The National Health Care Institute has completed its assessment whether asfotase alfa (Strensiq®) is interchangeable with a ...

   Report | 19-03-2020

10. Olaparib (Lynparza®) for the maintenance treatment of adult patients with carcinoma of the ovaries, tubes or peritoneum

    The National Health Care Institute has completed its assessment whether olaparib (Lynparza®) as a monotherapy for the maintenance ...

    Report | 19-03-2020